Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
News|Videos|February 25, 2026
Final Analysis of the Randomized Phase 2 ROSEWOOD Study of Zanubrutinib + Obinutuzumab vs Obinutuzumab Monotherapy in Patients With Relapsed/Refractory Follicular Lymphoma
Author(s)Judith Trotman, MD
ROSEWOOD rapid readout: zanubrutinib plus obinutuzumab boosts durable responses and progression-free survival in relapsed follicular lymphoma, with manageable long-term safety.
Advertisement
This media program features an expert-led presentation reviewing the final analysis of the randomized Phase 2 ROSEWOOD study evaluating zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. The program highlights key efficacy outcomes, durability of response, and safety findings based on extended follow-up, providing clinically relevant insights to inform treatment decision-making in heavily pretreated patients.
Advertisement
Related to this article
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
3
Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma
4
European Commission Approves Camizestrant Plus CDK4/6 Inhibition for Emergent ESR1-Mutated Advanced Breast Cancer
5